Chameleon Biosciences
San Anselmo
About Chameleon Biosciences
Chameleon is changing the way they treat genetic diseases using gene therapy to deliver corrective genes using multiple systemic dose administrations. Research indicates that 20-30% of all infant fatalities are due to genetic disorders, and for those who survive, treatment options are often limited. Recent breakthroughs in gene therapy are saving lives, but there's still a long way to go. At Chameleon, their goal is to ensure every child can be treated with lower doses and accurate target specificity over time as their condition requires. They are committed to every child and family who suffers from a genetic disorder. Their mission is to make sure every Belle, Abby and Marian live to their 10th birthdays, learn to drive, go to prom and someday have healthy children of their very own.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $14.2M
- Funding stage: Seed
- Last round: Seed (Nov 2022)
- Website: chameleonbiosci.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Genetics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/chameleon-biosciences-56744 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.